| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $205,797 | 1 | 25 |
Sells | $258,671 | 3 | 75 |
| BARABE TIMOTHY C | director | 1 | $205,797 | 0 | $0 | $205,797 |
| Miljkovic Milos | Chief Medical Officer | 0 | $0 | 1 | $24,367 | $-24,367 |
| Davis Blaine | Chief Financial Officer | 0 | $0 | 1 | $72,227 | $-72,227 |
| Brunn Carsten | President and CEO | 0 | $0 | 1 | $162,077 | $-162,077 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile …
Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $205,797 and sold $258,671 worth of Cartesian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $5.45M and sold $2.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BARABE TIMOTHY C (director) — $205,797.
The last purchase of 30,000 shares for transaction amount of $205,797 was made by BARABE TIMOTHY C (director) on 2025‑12‑04.
| 2026-01-06 | Sale | Brunn Carsten | President and CEO | 23,766 0.0902% | $6.82 | $162,077 | +5.18% | |
| 2026-01-06 | Sale | Davis Blaine | Chief Financial Officer | 10,591 0.0402% | $6.82 | $72,227 | +5.18% | |
| 2026-01-06 | Sale | Miljkovic Milos | Chief Medical Officer | 3,573 0.0136% | $6.82 | $24,367 | +5.18% | |
| 2025-12-04 | BARABE TIMOTHY C | director | 30,000 0.1147% | $6.86 | $205,797 | +6.96% | ||
| 2025-04-11 | SPRINGER TIMOTHY A | 42,750 0.1758% | $10.77 | $460,529 | -13.03% | |||
| 2025-04-10 | SPRINGER TIMOTHY A | 57,170 0.2285% | $10.47 | $598,524 | -10.42% | |||
| 2025-04-09 | SPRINGER TIMOTHY A | 49,155 0.1769% | $9.43 | $463,464 | -18.13% | |||
| 2025-03-20 | SPRINGER TIMOTHY A | 54,889 0.2073% | $15.59 | $855,593 | -38.86% | |||
| 2025-03-19 | SPRINGER TIMOTHY A | 20,234 0.0762% | $14.97 | $302,962 | -36.93% | |||
| 2025-03-18 | SPRINGER TIMOTHY A | 14,740 0.0562% | $14.42 | $212,599 | -33.15% | |||
| 2025-01-14 | SPRINGER TIMOTHY A | 4,022 0.0156% | $18.00 | $72,396 | -42.34% | |||
| 2025-01-13 | SPRINGER TIMOTHY A | 16,945 0.0631% | $17.35 | $293,958 | -43.21% | |||
| 2025-01-06 | Sale | Brunn Carsten | President and CEO | 8,708 0.032% | $16.83 | $146,575 | -40.61% | |
| 2025-01-06 | Sale | Davis Blaine | Chief Financial Officer | 4,028 0.0148% | $16.83 | $67,800 | -40.61% | |
| 2025-01-06 | Sale | Kurtoglu Metin | Chief Technology Officer | 2,458 0.009% | $16.83 | $41,374 | -40.61% | |
| 2025-01-06 | Sale | Jewell Christopher M | Chief Scientific Officer | 1,286 0.0047% | $16.83 | $21,646 | -40.61% | |
| 2025-01-06 | Sale | English Emily | Chief Operations Officer | 906 0.0033% | $16.83 | $15,250 | -40.61% | |
| 2025-01-06 | Sale | Miljkovic Milos | Chief Medical Officer | 948 0.0035% | $16.83 | $15,957 | -40.61% | |
| 2025-01-03 | Sale | Brunn Carsten | President and CEO | 8,563 0.033% | $16.72 | $143,190 | -37.51% | |
| 2025-01-03 | Sale | Davis Blaine | Chief Financial Officer | 3,961 0.0153% | $16.72 | $66,235 | -37.51% |
| BARABE TIMOTHY C | director | 54366 0.1797% | $348,486.06 | 2 | 0 | +25.47% |
| SPRINGER TIMOTHY A | 8643685 28.5691% | $55.41M | 19 | 0 | <0.0001% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$54,828,550 | 26 | -13.88% | $201.12M |
| Increased Positions | 37 | +48.05% | 1M | +17.89% |
| Decreased Positions | 32 | -41.56% | 2M | -31.61% |
| New Positions | 15 | New | 488,710 | New |
| Sold Out Positions | 15 | Sold Out | 997,627 | Sold Out |
| Total Postitions | 82 | +6.49% | 5M | -13.72% |
| Fmr Llc | $14,573.00 | 8.29% | 2.16M | -178,341 | -7.64% | 2025-09-30 |
| Blackrock, Inc. | $4,390.00 | 2.5% | 649,341 | -4,499 | -0.69% | 2025-09-30 |
| Siren, L.L.C. | $3,808.00 | 2.17% | 563,272 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,520.00 | 2% | 520,722 | +24,356 | +4.91% | 2025-09-30 |
| Mpm Bioimpact Llc | $2,569.00 | 1.46% | 380,000 | -306,007 | -44.61% | 2025-09-30 |
| Erste Asset Management Gmbh | $1,758.00 | 1% | 260,011 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $1,635.00 | 0.93% | 241,829 | +22,902 | +10.46% | 2025-09-30 |
| 683 Capital Management, Llc | $1,555.00 | 0.89% | 230,000 | +11,000 | +5.02% | 2025-09-30 |
| State Street Corp | $1,336.00 | 0.76% | 197,666 | +3,397 | +1.75% | 2025-09-30 |
| Northern Trust Corp | $617.00 | 0.35% | 91,289 | +8,345 | +10.06% | 2025-09-30 |